蒽环类药物米托蒽醌与育亨宾在晚期L 12010和P 388白血病中存在超相加协同作用。
Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.
作者信息
Osswald H, Youssef M
出版信息
J Cancer Res Clin Oncol. 1986;111(2):137-40. doi: 10.1007/BF00400752.
Abstract
The combination of mitoxantrone with lucanthone, a schistosomicidal and nonmyelotoxic agent, yielded a therapeutic synergism in L 1210 and P 388 leukemia with no increase in toxicity. In that combination the nonmyelotoxic lucanthone enabled the use of the optimal dose of mitoxantrone. The recent hypothesis that planar polycyclic aromatic compounds, mostly comprised by the term intercalators, intercalate with DNA or bind to DNA may need receiving with respect to membrane target sites.
摘要
米托蒽醌与一种杀血吸虫且无骨髓毒性的药物卢坎酮联合使用，在L 1210和P 388白血病中产生了治疗协同作用，且毒性未增加。在这种联合用药中，无骨髓毒性的卢坎酮使得能够使用米托蒽醌的最佳剂量。最近关于平面多环芳香化合物（大多由嵌入剂这一术语涵盖）嵌入DNA或与DNA结合的假说，可能需要从膜靶点的角度来审视。
相似文献
1
Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.蒽环类药物米托蒽醌与育亨宾在晚期L 12010和P 388白血病中存在超相加协同作用。
J Cancer Res Clin Oncol. 1986;111(2):137-40. doi: 10.1007/BF00400752.
2
Therapeutic activity of mitoxantrone and ametantrone against murine tumors.
Cancer Treat Rev. 1983 Dec;10 Suppl B:13-21. doi: 10.1016/0305-7372(83)90017-8.
3
Metoclopramide and nitrendipine are unable to enhance cytotoxicity of mitoxantrone in sensitive and resistant murine leukemias in vivo.
Arch Immunol Ther Exp (Warsz). 1997;45(2-3):249-53.
4
Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210.肌氨酸和脯氨酸二硫代氨基甲酸盐预处理可提高阿霉素、甲氨蝶呤、替尼泊苷、米托蒽醌或环己氯乙基亚硝脲对白血病L1210的治疗效果。
J Cancer Res Clin Oncol. 1990;116(5):448-52. doi: 10.1007/BF01612992.
5
Development of mitoxantrone.米托蒽醌的研发。
Invest New Drugs. 1985;3(2):85-93. doi: 10.1007/BF00174154.
6
In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia.
Oncology. 1990;47(2):166-9. doi: 10.1159/000226811.
7
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌：系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
8
Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.米托蒽醌对小鼠实验性肿瘤的抗肿瘤活性：与多种抗肿瘤抗生素的比较分析。
Cancer Chemother Pharmacol. 1982;8(2):157-62. doi: 10.1007/BF00255476.
9
A systematic overview of chemotherapy effects in acute myeloid leukaemia.急性髓系白血病化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
10
Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.两性霉素B（Fungizone）或脱氧胆酸钠无法改变移植性小鼠白血病的天然耐药性或敏感性。
Indian J Physiol Pharmacol. 1984 Jan-Mar;28(1):21-6.
引用本文的文献
1
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.米托蒽醌。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007.
本文引用的文献
1
A SYSTEMATIC INVESTIGATION OF THIOXANTHEN-9-ONES AND ANALOGS AS POTENTIAL ANTITUMOR AGENTS.噻吨-9-酮及其类似物作为潜在抗肿瘤药物的系统研究
J Med Chem. 1963 Mar;6:185-91. doi: 10.1021/jm00338a022.
2
3
Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.一种新型抗肿瘤药物1,4 - 二羟基 - 5,8 - 双[[2 - [(2 - 羟乙基)氨基] - 乙基]氨基] - 9,10 - 蒽二酮与核酸的相互作用。
Biochem Pharmacol. 1981 Feb 1;30(3):231-40. doi: 10.1016/0006-2952(81)90083-6.
4
Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.米托蒽醌对小鼠实验性肿瘤的抗肿瘤活性：与多种抗肿瘤抗生素的比较分析。
Cancer Chemother Pharmacol. 1982;8(2):157-62. doi: 10.1007/BF00255476.
5
The anticancer agent adriamycin can be actively cytotoxic without entering cells.抗癌药物阿霉素在不进入细胞的情况下也可具有细胞毒性。
Science. 1982 Jul 16;217(4556):248-50. doi: 10.1126/science.7089561.
6
Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents.
Cancer Treat Rep. 1982 May;66(5):1187-200.
7
Biologic and biochemical effects of mitoxantrone.米托蒽醌的生物学和生物化学效应。
Semin Oncol. 1984 Sep;11(3 Suppl 1):3-10.
8
Aza analogues of lucanthone: synthesis and antitumor and bactericidal properties.卢卡酮的氮杂类似物：合成及其抗肿瘤和杀菌特性
J Med Chem. 1983 Sep;26(9):1329-33. doi: 10.1021/jm00363a022.
9
Molecular and biochemical pharmacology of mitoxantrone.米托蒽醌的分子与生化药理学
Cancer Treat Rev. 1983 Dec;10 Suppl B:3-11. doi: 10.1016/0305-7372(83)90016-6.
10
Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracenedione antineoplastic agents.米托蒽醌和氨茴环素（两种新型蒽二酮抗肿瘤药）对阿霉素刺激的微粒体脂质过氧化的抑制作用
Biochem Biophys Res Commun. 1982 Oct 15;108(3):1346-52. doi: 10.1016/0006-291x(82)92148-9.
Zotero 插件